Background and objectives
Results from observational studies suggest an association of red meat intake with risk of type 2 diabetes mellitus (T2D). However, results from randomized controlled trials (RCTs) have not clearly supported a mechanistic link between red meat intake and T2D risk factors. Therefore, a systematic review and meta-analysis were conducted on RCTs evaluating the effects of diets containing red meat (beef, pork, lamb, etc.), compared to diets with lower or no red meat, on markers of glucose homeostasis in adults.
A search of PubMed and CENTRAL yielded 21 relevant RCTs. Pooled estimates were expressed as standardized mean differences (SMDs) between the red meat intervention and the comparator intervention with less or no red meat.
Compared to diets with reduced or no red meat intake, there was no significant impact of red meat intake on insulin sensitivity (SMD: −0.11; 95% CI: −0.39, 0.16), insulin resistance (SMD: 0.11; 95% CI: −0.24, 0.45), fasting glucose (SMD: 0.13; 95% CI: −0.04, 0.29), fasting insulin (SMD: 0.08; 95% CI: −0.16, 0.32), glycated hemoglobin (HbA1c; SMD: 0.10; 95% CI: −0.37, 0.58), pancreatic beta-cell function (SMD: −0.13; 95% CI: −0.37, 0.10), or glucagon-like peptide-1 (GLP-1; SMD: 0.10; 95% CI: −0.37, 0.58). Red meat intake modestly reduced postprandial glucose (SMD: −0.44; 95% CI: −0.67, −0.22; P < 0.001) compared to meals with reduced or no red meat intake. The quality of evidence was low to moderate for all outcomes.
The results of this meta-analysis suggest red meat intake does not impact most glycemic and insulinemic risk factors for T2D. Further investigations are needed on other markers of glucose homeostasis to better understand whether a causal relationship exists between red meat intake and risk of T2D.
Results from observational studies suggest that dietary patterns higher in red meat intake, compared to patterns lower in red meat, are associated with increased risk for T2D [1,2,3,4]. However, results from RCTs have been mixed in demonstrating a mechanistic link between red meat intake and the T2D risk factor profile [5,6,7]. Furthermore, the recommendations for red meat intake have differed among scientific organizations. The 2020 Dietary Guidelines Advisory Committee report reconfirmed the findings of the 2015 Dietary Guidelines Advisory Committee that there is “moderate” scientific evidence indicating a dietary pattern limiting intake of red and processed meat, sugar-sweetened foods/drinks, refined grains and high-fat dairy and higher in fruits, vegetables, and whole grains reduces the risk of T2D . However, the Nutritional Recommendations (NutriRECS) Consortium evaluated 23 cohort studies with 1.4 million participants and concluded there was low to very-low certainty of evidence that decreasing unprocessed red meat or processed meat intake may result in very small reductions in the risk for type 2 diabetes [6, 9].
Insulin resistance is one of the characteristics of T2D and several controlled feeding studies have evaluated the impact of higher protein or red meat intakes on whole-body insulin sensitivity, compared to diets with lower red meat intake [10,11,12,13,14]. While insulin sensitivity is one key determinant of glucose tolerance, others include pancreatic beta- and alpha-cell function, hepatic glucose production, adipose tissue lipolysis, and incretin responses to food intake [10, 15,16,17,18]. Relatively little research has been completed in humans to assess possible mechanistic links between red meat intake and determinants of glucose tolerance other than insulin sensitivity. The purpose of this review and meta-analysis is to assess the status of the available data on mechanisms through which red meat intake might affect T2D risk from dietary intervention studies in humans, with a focus on the established determinants of glucose tolerance .
Materials and methods
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed for performing the systematic review and meta-analyses . A comprehensive literature search was conducted using the PubMed and CENTRAL databases to identify papers through December of 2021. The search was designed to identify publications of RCTs that examined red meat intake and outcomes related to risk factors for T2D, including insulin sensitivity [e.g., Matsuda Index, Quantitative Insulin Sensitivity Check Index (QUICKI), Predicted M (PREDIM), homeostatic model of insulin sensitivity (HOMA-2%S), insulin resistance [e.g., homeostatic model of insulin resistance (HOMA-IR)], fasting glucose and insulin, postprandial glucose and insulin, pancreatic beta-cell function, markers of lipolysis (e.g. free fatty acids), incretins (e.g., GLP-1, gastric inhibitory peptide), insulin-like growth factor-1, serine kinases, hepatic glucose production and uptake, glucagon, kidney glucose reabsorption, branched-chain amino acids and trimethylamine N-oxide. Full search term details are provided in Supplemental Table 1.
Inclusion and exclusion criteria
Inclusion criteria consisted of RCTs conducted in adult humans (≥18 y of age), English language publications, fresh/minimally processed or further processed red meat (e.g., beef, pork, lamb, etc.) as the main intervention compared to a control without red meat or with a lower level of red meat, and a baseline and post-treatment measure of fasting and/or postprandial glycemia, insulinemia, insulin sensitivity, pancreatic beta-cell function, or other determinants of glucose tolerance such as hepatic glucose output, incretin responses, or free fatty acid levels in circulation. Exclusion criteria included observational studies (cross-sectional, retrospective, or prospective cohorts), case-control or single-arm studies with no control condition, studies in animals or in vitro, multicomponent interventions where the effect of red meat cannot be determined (e.g., energy-restricted diets), studies comparing different types of red meat without a lower or no red meat control diet, studies based on red meat components (e.g., iron, carnosine) or dietary supplements, interventions administered via tube feeding or enteral nutrition, studies in children (<18 y of age) or pregnant/lactating women, and studies in subjects with a chronic disease, with the exception of T2D, overweight/obesity, prediabetes, or metabolic syndrome. These chronic diseases were included as they are related to increased risk of T2D. The original protocol excluded interventions with mixed animal proteins compared to diets lower in animal proteins; however, this led to the exclusion of several studies that varied red meat intake. Therefore, the protocol was altered to include studies comparing higher and lower animal protein intake and to include a subgroup analysis on studies varying only in red meat intake.
Screening and data extraction
After screening of titles and abstracts, full texts of all publications identified as potentially eligible were obtained for further review by two independent reviewers. Publications that were unclear with respect to eligibility were resolved by discussion with the research team. Reference lists from eligible publications were reviewed to determine any additional studies for inclusion. Following the full-text review, PICO (population, intervention, comparator, and outcome) data were extracted from the eligible studies into a database by one reviewer and verified for accuracy by a second reviewer. All discrepancies were resolved by discussion among the reviewers and referencing the original publication. In studies where outcomes were reported in bar graphs, Engauge Digitizer software version 4.1 (http://markummitchell.github.io/engauge-digitizer/) was used to estimate the means and standard deviation (SD) or standard error of the mean (SEM) in the graphs for inclusion in the database. If studies did not report SDs or SEMs for an outcome, the SD was estimated as the maximum SD reported by other studies with the same outcome. Sensitivity analyses were completed to assess different SD assumptions for such studies. Since results did not materially differ, only those with maximum SD are presented.
Assessment of study quality
Risk of bias for each relevant outcome within a study was assessed with the Cochrane risk of bias tool for randomized trials . The quality of the evidence for each outcome was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method .
Meta-analyses were completed using Comprehensive Meta-analysis (CMA) Software version 3 (Biostat, Englewood, NJ). Insulin sensitivity was pre-specified as the primary outcome. All insulin sensitivity measures were analyzed together (Matsuda Index, QUICKI, PREDIM, HOMA-2%S, insulin sensitivity index, and inverse of HOMA-IR) as were all beta-cell function measures (HOMA-2%B, Disposition Index). HOMA-IR was also analyzed separately as a marker of insulin resistance. The primary analysis used pooled SMD estimates (red meat diet vs. lower or no red meat diet) and 95% confidence intervals (CI) for insulin sensitivity, HOMA-IR, fasting glucose and insulin, glycated hemoglobin (HbA1c), pancreatic beta-cell function, and AUC of postprandial glucose, insulin, and GLP-1. Statistical significance for individual study and pooled SMDs was declared when the 95% CI did not include the null value of 0 (i.e., p value < 0.05). SMDs express the effect size relative to the standard deviation and do not have units. This approach enables pooling of measurements taken using different scales and measurement techniques (e.g., Matsuda index, QUICKI, PREDIM, etc.) . SMDs should not be interpreted as true differences in means between the test and control because the difference in means is expressed as a fraction of a standard deviation. Studies were weighted according to the inverse of the variance of each study’s effect using random effects models. Random effects models were chosen due to the heterogeneity in study designs, populations, dietary interventions, and study length. Sensitivity analyses included fixed effects models and removal of one study at a time to determine if any study was substantially influencing the results. Subgroup analyses were performed for the type of animal protein in the intervention (red meat only or mixed animal protein), amount of red meat consumed (≤ median or > median of the included studies), comparator diet (plant protein, refined carbohydrate, other animal protein), and health status (healthy, overweight/obese, metabolic dysfunction, T2D). Metabolic dysfunction was defined as subjects with metabolic syndrome or at least one indicator of impaired cardiometabolic health, including impaired glucose tolerance, impaired fasting glucose, or hypertension. The magnitude of effect sizes was interpreted as <0.40 = small, 0.40–0.70 = moderate and >0.70 = large .
Data from parallel and crossover RCTs were entered into the CMA software using the following data entry formats: “Independent groups (means, SD)” and “Paired groups (means, SD),” respectively. SMDs and corresponding SEMs for individual studies were computed by the software using the methods for independent groups and matched groups described by Borenstein et al.  and an imputed between-treatment correlation of 0.50 for matched groups. Sensitivity analyses were performed for the primary analyses assuming no between-treatment correlation for matched groups and the results were similar. For multiple comparisons within a study (i.e., comparisons that shared a common active or control), individual effect size estimates and variances were computed for all comparisons within a study. A pooled effect size estimate was then computed as the weighted average of the individual effect size estimates. The corresponding pooled effect variance was computed as the variance of a linear combination of two or more variables (i.e., average of two or more effect size estimates) using between-comparison correlations equivalent to the weighted average of the between-active (red meat) correlation and the between-control correlation . A single pooled effect size estimate and variance was then included in the analysis for each study with multiple comparisons. When multiple comparisons included in a subgroup varied from those included in the primary analysis, the above steps were repeated prior to running the subgroup analysis. In the analysis of insulin sensitivity, individual effect size estimates and variances were pooled similarly for studies that reported multiple measures of insulin sensitivity.
Statistical heterogeneity across studies was assessed using Cochran’s Q and the I2 statistic. An I2 value of ≥40% was used to designate moderate or higher heterogeneity, in accordance with the recommendations in the Cochrane Handbook . Chi-square test statistics and p values are reported for Cochran’s Q tests for heterogeneity across studies and between subgroups. The presence of publication bias was assessed by Egger’s test and examining funnel plots measuring the SEM as a function of the SMD.
A flow diagram summarizing the literature search process is shown in Fig. 1. Thirty-two articles were uncovered in the search and an additional 18 were identified in the reference lists of full-text articles. Twenty-three of these were excluded for not meeting the intervention or comparator criteria or not including an outcome of interest (Supplemental Table 2), leaving 27 articles for inclusion in the systematic review. Of these, 4 included incomplete data (e.g., missing baseline or post-treatment values) or data in an unusable form (e.g., timepoint data vs AUC). Two studies reported additional outcomes of interest, but two comparisons were insufficient to conduct a meta-analysis; therefore, these were excluded (Supplemental Table 2). Overall, 21 studies could be included in the meta-analysis [11,12,13, 27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44]. The only outcomes with sufficient comparisons (≥3) to include in a meta-analysis were fasting glucose, fasting insulin, insulin sensitivity (all measures), HOMA-IR, postprandial glucose, postprandial insulin, HbA1c, pancreatic beta-cell function, and GLP-1. There were insufficient comparisons (<3) for markers of lipolysis, insulin-like growth factor-1, serine kinases, hepatic glucose production and uptake, glucagon, kidney glucose reabsorption, branched-chain amino acids, and trimethylamine N-oxide.
Study characteristics are in Supplemental Table 3. Fourteen of the studies were crossover [11, 12, 28, 31,32,33,34,35,36,37, 39,40,41,42] and seven were parallel [14, 27, 29, 34, 38, 43, 44]. Four of the studies were acute (postprandial) feeding trials and the remainder ranged from 1 week  to 10 weeks , with most studies in the range of 4–8 weeks [11,12,13, 28, 30, 34, 36, 38,39,40,41,42,43,44]. Only seven studies included healthy individuals [27,28,29, 32, 36, 37, 41], with the remaining studies in subjects with metabolic syndrome, prediabetes, T2D, and/or overweight/obesity. The studies in healthy individuals often included normal weight and overweight or obese subjects but did not stratify the results by BMI classification. The comparator diet to the red meat exposure was different in several studies. Ten studies compared a red meat or mixed animal protein diet to a plant protein diet [14, 27, 28, 31, 32, 34, 37,38,39, 42], while seven studies compared red meat to other animal protein sources (e.g., dairy, seafood, white meat) [12, 13, 35, 36, 40, 41, 43]. Four studies used red meat to replace refined carbohydrate [11, 29, 33, 44].
Diets containing red meat and insulin sensitivity
Overall, 24 comparisons reported in 15 studies were included in the analysis of the impact of diets containing red meat on insulin sensitivity. There was no significant impact of diets containing red meat, compared to diets with less or no red meat intake, on insulin sensitivity (Fig. 2, SMD: −0.11, 95% CI: −0.39, 0.16) but there was substantial heterogeneity between studies (Q = 87.8, P < 0.001, I2 = 84.0%). A sensitivity analysis with one study removed at a time showed no study substantially influenced the results (Supplemental Table 4).
Findings from subgroup analyses are shown in Table 1. There was a small and marginally significant improvement in insulin sensitivity with red meat intake in individuals with T2D (SMD: 0.29; 95% CI: 0.00, 0.57; P = 0.049) compared to those consuming less red meat. This was not observed in healthy individuals or individuals with metabolic dysfunction. No other significant differences were found with subgroups evaluating type of meat, amount of red meat intake, or comparator diet.
Diets containing red meat and HOMA-IR
Overall, 13 comparisons reported in 11 studies were included in the analysis of the impact of diets containing red meat on HOMA-IR. There was no significant impact of diets containing red meat, compared to diets with less or no red meat intake, on HOMA-IR (Fig. 3; SMD: 0.11; 95% CI: −0.24, 0.45) but there was substantial heterogeneity between studies (Q = 64.4, P < 0.001, I2 = 84.5%). A sensitivity analysis with one study removed at a time showed no study substantially influenced the results (Supplemental Table 4). No significant differences were found in subgroup analyses (Table 1).
Diets containing red meat and fasting glucose
Twenty-three comparisons reported in 16 studies were included in the analysis of the impact of diets containing red meat on fasting glucose. There was no significant impact of diets containing red meat, compared to diets with less or no red meat intake, on fasting glucose (Fig. 4; SMD: 0.13; 95% CI: −0.04, 0.29) but there was moderate and significant heterogeneity between studies (Q = 36.1, P = 0.002; I2 = 58.4%). A sensitivity analysis with one study removed at a time showed no study substantially influenced the results (Supplemental Table 4).
Subgroup analyses showed diets increasing red meat intake alone resulted in a marginally significant increase in fasting glucose (Table 1; SMD: 0.20; 95% CI: 0.00, 0.39; P = 0.049) not observed in diets increasing all animal protein intake. Diets containing red meat intake also significantly increased fasting glucose in subjects with metabolic dysfunction (SMD: 0.34; 95% CI: 0.17, 0.51; P < 0.001), but the effect size was small. In contrast, diets containing red meat lowered fasting glucose in subjects with T2D (SMD: −0.47; 95% CI: −0.90, −0.05; P = 0.030). However, only three comparisons in two studies were included in this subgroup, so these results should be interpreted with caution. Fasting glucose was also significantly increased in studies feeding more than the median intake of red meat (113 g/d) (SMD: 0.17; 95% CI: 0.01, 0.34; P = 0.043).
Diets containing red meat and fasting insulin
Twenty-three comparisons reported in 16 studies were included in the analysis of the impact of diets containing red meat on fasting insulin. There was no significant impact of diets containing red meat compared to diets with less or no red meat on fasting insulin (Fig. 5; SMD: 0.08; 95% CI: −0.16, 0.32) but there was substantial heterogeneity between studies (Q = 74.3, P < 0.001, I2 = 79.8%). A sensitivity analysis with one study removed at a time showed no study substantially influenced the results (Supplemental Table 4). No significant differences were found in subgroup analyses (Table 1).
Diets containing red meat and postprandial glucose and insulin
Three comparisons reported in three studies were included in the analysis of the impact of diets containing red meat on postprandial glucose. Red meat intake resulted in significantly lower postprandial glucose compared to diets with less or no red meat intake (Fig. 6; SMD: −0.44; 95% CI: −0.67, −0.22; P < 0.001) with no significant heterogeneity between studies (Q = 1.60, p = 0.450, I2 = 0%). Considering the small number of studies and design differences, caution is warranted in interpretation of these results. For example, one study replaced available carbohydrates with red meat while other studies matched macronutrient content. Also, the populations studied only included subjects with metabolic dysfunction or T2D. A sensitivity analysis with one study removed at a time showed no study substantially influenced the results (Supplemental Table 4). Three comparisons reported in three studies were included in the analysis of the impact of red meat on postprandial insulin. There was no significant effect of red meat intake, compared to diets with less or no red meat, on postprandial insulin (Supplemental Fig. 1; SMD: −0.70, 95% CI: −1.50, 0.11) but with substantial heterogeneity between studies (Q = 18.5, P < 0.001, I2 = 89.2%).
Diets containing red meat and HbA1c, pancreatic beta-cell function, and GLP-1
Few studies included the impact of red meat intake on HbA1c, pancreatic beta-cell function, or GLP-1. There were no significant effects of red meat diets, compared to diets with lower or no red meat on HbA1c (Supplemental Fig. 2), pancreatic beta-cell function (Supplemental Fig. 3), or GLP-1 (Supplemental Fig. 4). There was also no significant heterogeneity between the studies for these outcomes, except for GLP-1 (Q = 21.8, P < 0.001, I2 = 86.2%). In a sensitivity analysis, red meat intake significantly reduced GLP-1 with removal of the study by Douglas et al. .
Quality of evidence
The quality of evidence as assessed by GRADE criteria is summarized in Table 2. Overall, the evidence for most outcomes was rated as low to moderate. The evidence rating was downgraded for some outcomes due to concerns about inconsistency, imprecision, and some indirectness. The risk of bias assessments on the individual studies is in Supplemental Table 5. The risk of bias was rated “low” or “some concerns” for most studies. The funding source is not a component in Cochrane ROB; however, a qualitative assessment of results suggested no material differences by funding source category. Ten publications were from studies funded partly or solely by industry or trade associations (animal and plant-based foods) and 11 were funded by the university and governmental sources. Publication bias was not evident for any outcomes, except possibly GLP-1, based on Egger’s regression (Supplemental Table 6).
While results from observational studies have suggested an association of red meat intake with T2D incidence, the results of this meta-analysis of RCTs did not show an effect of red meat on glycemic and insulinemic biomarkers associated with the development of T2D. There was no significant effect of diets containing red meat, compared to diets with little or no red meat, on fasting glucose, fasting insulin, postprandial insulin, insulin sensitivity, HOMA-IR, HbA1c, pancreatic beta-cell function, or GLP-1. In a small number of studies, red meat intake lowered postprandial glucose. The lower postprandial glucose may be partly due to the replacement of refined carbohydrate with protein in one study , although another study reported higher sugar and lower fiber content in the red meat meal compared to the control meal . With only three studies of varying designs and in subjects with T2D or metabolic dysfunction, more evidence is needed before firm conclusions can be drawn.
Findings from the present meta-analysis are consistent with those reported in a recent review by O’Connor et al.  who also found no effect of ≥0.5 servings of red meat/day, compared with <0.5 servings per day, on HOMA-IR, fasting glucose, fasting insulin, and HbA1c in disease-free individuals at risk of T2D. The present meta-analysis included studies in individuals with metabolic syndrome and T2D and additional outcomes of pancreatic beta-cell function and GLP-1, and still did not find an overall effect of red meat intake on markers of glycemia and insulinemia. However, when evaluating outcomes by health status of the participants, some differences in response to red meat intake did emerge. Fasting glucose was significantly increased in individuals with metabolic dysfunction, but the effect was small (SMD 0.34; 95% CI: 0.17, 0.51), corresponding to an increase of approximately 0.12 ± 0.03 mmol/L. The change in fasting glucose did not coincide with changes in insulin sensitivity or resistance. Therefore, the clinical relevance of the increase in fasting glucose in individuals with metabolic dysfunction is uncertain. It is possible that red meat intake may be impacting pancreatic alpha- or beta-cell function or hepatic glucose production, which could increase fasting glucose. Pancreatic beta-cell function was not significantly impacted by red meat intake the present meta-analysis, yet with only three studies and mixed results, the available evidence is limited and more research in this area is needed. Compounds in red meats, such as iron, have been shown to enhance formation of reactive oxygen species, which could plausibly affect pancreatic beta-cell function . Additionally, iron in the liver may impact hepatic insulin extraction, possibly increasing hepatic glucose production [45, 46].
Interestingly, a significant reduction in fasting glucose (SMD = −0.47; 95% CI: −0.90, −0.05) and marginally significant increase in insulin sensitivity (SMD = 0.29; 95% CI: 0.00, 0.57) was observed in subjects with T2D. The decrease in fasting glucose corresponded to 1.02 mmol/L with a SD for baseline fasting glucose of 2.78 mmol/L. However, these results should be interpreted with caution since only 3 studies included subjects with T2D and there were some concerns about quality in two of these studies. One reported a higher baseline fasting glucose and HbA1c in subjects randomized to the animal protein compared to the plant protein diets , while another study  reported a small but statistically significant decrease in BMI during the interventions, which may have contributed to the trends toward improved fasting glucose reported in these studies. One study report noted that the intervention diets were also healthier than the typical diets consumed, containing approximately 12% more protein and 10% less fat . Thus, there may be effects from providing an overall healthier diet, independent of protein source. These issues underscore the need for high-quality, well-controlled studies in individuals with T2D to better elucidate the effect of red meat intake on glycemia and insulinemia in this population.
The comparator diet, amount of red meat, or type of meat in the intervention (red meat alone or mix of animal proteins) did not generally influence glycemic and insulinemic outcomes. While the overall analysis did not show an impact of red meat on fasting glucose, subgroup analyses demonstrated an increase in fasting glucose in studies increasing red meat alone, studies replacing carbohydrate with red meat, and studies feeding greater than the median intake of red meat (113 g/d). Most studies increasing red meat alone (7 of 10), replacing carbohydrate with red meat (3 of 4), and feeding amounts greater than the median (5 of 7), were in subjects with metabolic dysfunction. In fact, in all subgroups, the only studies reporting directional increases in fasting glucose were in subjects with metabolic dysfunction. Thus, the increase in fasting glucose in these subgroups may be partially explained by the characteristics of the subjects studied (i.e., with metabolic dysfunction but without T2D).
Interestingly, there was no effect on glycemia or insulinemia when red meat was replaced with plant proteins, despite results from epidemiological studies suggesting a positive association between animal protein intake but not plant protein and risk for T2D [47, 48]. Many studies used soy products, which have been associated with a reduced risk of T2D and improvements in glucose homeostasis [49,50,51]. However, findings from prospective cohort studies have suggested the benefits of soy may be due to isoflavones rather than type of protein , and most studies in the current meta-analysis did not evaluate or control the isoflavone contents of the diets.
The results of the current meta-analysis, along with those from other meta-analyses of RCTs , are consistent in showing red meat intake does not impact most glycemic and insulinemic risk factors for T2D. However, observational data suggest a positive association between red meat intake and risk for T2D [1, 4, 6, 9, 52, 53]. This discrepancy may partially be explained by other factors associated with red meat intake that may increase the risk for T2D, resulting in residual confounding. Compared to individuals who consume less red meat, those that consume more red meat also tend to be more inactive, eat fewer fruits, vegetables, and whole grains, are more likely to be current smokers, drink alcohol, and have a higher mean BMI [2, 4]. RCTs ensure similar distribution of known and unknown factors associated with the study outcome across groups or conditions and are thus less susceptible to bias and confounding. Most of the studies included in the current meta-analysis also provided unprocessed red meat, which may differentially impact glycemia and insulinemia compared to processed red meat. Many observational studies do not differentiate between unprocessed and processed red meat [1, 9, 53] but those that do tend to find a stronger association of processed meat to risk of T2D [2,3,4]. Additional studies are needed on processed meats to further elucidate if other processing constituents, such as sodium or nitrates, may be contributing to risk of T2D. It is also possible that mechanisms other than those investigated, or that require exposure over longer periods, could contribute to the observed associations between red meat intake and T2D incidence. Most studies were 4 to 8 weeks in duration so longer studies would be beneficial to understand longer-term impacts of red meat intake. Additional research is needed to investigate effects of red meat consumption on other mechanisms affecting glucose tolerance, particularly pancreatic alpha- and beta-cell function and regulation of hepatic glucose production.
The quality of the evidence for most outcomes was low due to substantial inconsistency, some indirectness, and moderate imprecision. Substantial inconsistency was noted in analyses with high heterogeneity not completely accounted for by subgroup analyses. Some indirectness was identified in that most studies were not in healthy subjects, but rather individuals already at risk for T2D due to other metabolic dysfunctions, including metabolic syndrome or elevated blood lipids. Therefore, to understand if red meat intake influences glycemic and insulinemic outcomes that could increase the risk of developing T2D, it is important to pursue additional studies in healthy individuals without pre-existing conditions or risk factors.
A strength of this meta-analysis is the use of SMDs, which allowed for multiple measurements of insulin sensitivity and insulin resistance to be combined for a more robust analysis. Additionally, multiple subgroup and sensitivity analyses allowed for greater insight into study design factors that may have contributed to the outcomes, including health status, comparator diet, and the amount of red meat in the diet. The exclusion of weight-loss diets may be considered a limitation of the current meta-analysis. However, weight loss can independently impact T2D risk factors, regardless of diet, making it difficult to determine the effects of red meat intake independent of weight loss. The recent meta-analysis by O’Connor et al.  included weight loss studies and the findings were similar to those of the present meta-analysis. It is also possible that red meat could be impacting other mechanistic risk factors for T2D, such as hepatic glucose production, or incretins beyond GLP-1, but the paucity of such studies limited the ability to include these outcomes in the analysis. It was not possible to examine the effect of red meat processing and fat content on glycemic and insulinemic outcomes due to most studies including unprocessed red meat or not specifying the type of red meat included in the intervention.
In summary, compared to diets containing less or no red meat, diets containing red meat did not impact glycemic and insulinemic risk factors for T2D, including fasting glucose, fasting insulin, insulin sensitivity, HbA1c, pancreatic beta-cell function, and GLP-1, but did reduce postprandial glycemia in a small number of studies. Individuals with metabolic dysfunction and pre-existing risk factors for T2D may respond differently to red meat intake, as evidenced by an increase in fasting glucose in the subset with metabolic dysfunction and this deserves further investigation. The impact of red meat intake on individuals with T2D should also be further investigated as there were few studies in these individuals, but some indication of improvements in glycemia and insulinemia. These findings reinforce the importance of and need for more high-quality RCTs to provide data relevant to determining whether the association between red meat intake and risk of diabetes is causal.
Data reviewed and analyzed during this meta-analysis is available from the corresponding author upon reasonable request.
Tian S, Xu Q, Jiang R, Han T, Sun C, Na L. Dietary protein consumption and the risk of type 2 diabetes: a systematic review and meta-analysis of cohort studies. Nutrients. 2017;9:982.
Pan A, Sun Q, Bernstein AM, Schulze MB, Manson JE, Stampfer MJ, et al. Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med. 2012;172:555–63.
Pan A, Sun Q, Bernstein AM, Schulze MB, Manson JE, Willett WC, et al. Red meat consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. Am J Clin Nutr. 2011;94:1088–96.
Micha R, Michas G, Mozaffarian D. Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes–an updated review of the evidence. Curr Atheroscler Rep. 2012;14:515–24.
Zeraatkar D, Johnston BC, Bartoszko J, Cheung K, Bala MM, Valli C, et al. Effect of lower versus higher red meat intake on cardiometabolic and cancer outcomes: a systematic review of randomized trials. Ann Intern Med. 2019;171:721–31.
Johnston BC, Zeraatkar D, Han MA, Vernooij RW, Valli C, El Dib R, et al. Unprocessed red meat and processed meat consumption: dietary guideline recommendations from the Nutritional Recommendations (NutriRECS) Consortium. Ann Intern Med. 2019;171:756–64.
O’Connor LE, Kim JE, Clark CM, Zhu W, Campbell WW. Effects of total red meat intake on glycemic control and inflammatory biomarkers: a meta-analysis of randomized controlled trials. Adv Nutr. 2020;12:115–27.
Dietary Guidelines Advisory Committee. Scientific Report of the 2020 Dietary Guidelines Advisory Committee: Advisory Report to the Secretary of Agriculture and the Secretary of Health and Human Services: United States Department of Agriculture (USDA) and the Department of Health and Human Services (HHS). Washington, DC; 2020.
Zeraatkar D, Han MA, Guyatt GH, Vernooij RW, El Dib R, Cheung K, et al. Red and processed meat consumption and risk for all-cause mortality and cardiometabolic outcomes: a systematic review and meta-analysis of cohort studies. Ann Intern Med. 2019;171:703–10.
DeFronzo RA. From the triumvirate to the “ominous octet”: a new paradigm for the treatment of type 2 diabetes mellitus. Clin Diabet. 2009;10:101–28.
Maki K, Wilcox M, Dicklin M, Buggia M, Palacios O, Maki C, et al. Substituting lean beef for carbohydrate in a healthy dietary pattern does not adversely affect the cardiometabolic risk factor profile in men and women at risk for type 2 diabetes. J Nutr. 2020;150:1824–33.
O’Connor LE, Paddon-Jones D, Wright AJ, Campbell WW. A Mediterranean-style eating pattern with lean, unprocessed red meat has cardiometabolic benefits for adults who are overweight or obese in a randomized, crossover, controlled feeding trial. Am J Clin Nutr. 2018;108:33–40.
Turner KM, Keogh JB, Clifton PM. Red meat, dairy, and insulin sensitivity: a randomized crossover intervention study. Am J Clin Nutr. 2015;101:1173–9.
Hassanzadeh-Rostami Z, Hemmatdar Z, Pishdad GR, Faghih S. Moderate consumption of red meat, compared to soy or non-soy legume, has no adverse effect on cardio-metabolic factors in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2021;129:429–37.
DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin. 2004;88:787–835.
Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissén M, et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2005;54:166–74.
Meier JJ, Nauck MA. Incretins and the development of type 2 diabetes. Curr Diabetes Rep. 2006;6:194–201.
Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Investig. 1989;84:205–13.
Moher D, Liberati A, Tetzlaff J, Altman DG, The Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.
Higgins JP, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. editors. Cochrane handbook for systematic reviews of interventions, vol. 6. John Wiley & Sons. Chichester (UK). Cochrane; 2019.
Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, et al. Interpreting results and drawing conclusions. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. (eds.). John Wiley & Sons. Chichester (UK). Cochrane handbook for systematic reviews of interventions; 2019. p. 403–31.
Borenstein M, Hedges LV, Higgins J, Rothstein HR (eds). Effect sizes based on means. In: Introduction to meta‐analysis. John Wiley & Sons. Chichester (UK); 2009. p. 21–32.
Borenstein M, Hedges LV, Higgins J, Rothstein HR (eds). Multiple outcomes or time-points within a study. In: Introduction to meta‐analysis. John Wiley & Sons. Chichester (UK); 2009, p. 225–38.
Deeks J, Higgins J, Altmann D. Chapter 10: analysing data and undertaking meta-analyses. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. (editors). Cochrane handbook for systematic reviews of interventions, vol. 6.0. John Wiley & Sons. Chichester (UK). Cochrane; 2019.
Coelho MOC, Monteyne AJ, Dirks ML, Finnigan TJA, Stephens FB, Wall BT. Daily mycoprotein consumption for 1 week does not affect insulin sensitivity or glycaemic control but modulates the plasma lipidome in healthy adults: a randomised controlled trial. Br J Nutr. 2021;125:147–60. https://doi.org/10.1017/s0007114520002524.
Crimarco A, Springfield S, Petlura C, Streaty T, Cunanan K, Lee J, et al. A randomized crossover trial on the effect of plant-based compared with animal-based meat on trimethylamine-N-oxide and cardiovascular disease risk factors in generally healthy adults: Study With Appetizing Plantfood—Meat Eating Alternative Trial (SWAP-MEAT). Am J Clin Nutr. 2020;112:1188–99.
Mitchell SM, Milan AM, Mitchell CJ, Gillies NA, D’Souza RF, Zeng N, et al. Protein intake at twice the RDA in older men increases circulatory concentrations of the microbiome metabolite trimethylamine-N-oxide (TMAO). Nutrients. 2019;11:2207–21.
Hassanzadeh-Rostami Z, Hemmatdar Z, Pishdad GR, Faghih S. Moderate consumption of red meat, compared to soy or non-soy legume, has no adverse effect on cardio-metabolic factors in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2019;129:429–37.
Kahleova H, Tura A, Klementova M, Thieme L, Haluzik M, Pavlovicova R, et al. A plant-based meal stimulates incretin and insulin secretion more than an energy- and macronutrient-matched standard meal in type 2 diabetes: a randomized crossover study. Nutrients. 2019;11:486–97.
Klementova M, Thieme L, Haluzik M, Pavlovicova R, Hill M, Pelikanova T, et al. A plant-based meal increases gastrointestinal hormones and satiety more than an energy- and macronutrient-matched processed-meat meal in T2D, obese, and healthy men: a three-group randomized crossover study. Nutrients. 2019;11. https://doi.org/10.3390/nu11010157
Palacios OM, Edirisinghe I, Wilcox ML, Burton-Freeman B, Xiao D, Maki KC. A lean pork-containing breakfast reduces hunger and glycemic response compared to a refined carbohydrate-containing breakfast in adults with prediabetes. J Am Coll Nutr. 2018;37:293–301.
Sucher S, Markova M, Hornemann S, Pivovarova O, Rudovich N, Thomann R, et al. Comparison of the effects of diets high in animal or plant protein on metabolic and cardiovascular markers in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab. 2017;19:944–52.
Turner KM, Keogh JB, Clifton PM. Acute effect of red meat and dairy on glucose and insulin: a randomized crossover study. Am J Clin Nutr. 2016;103:71–6.
Aadland EK, Graff IE, Lavigne C, Eng O, Paquette M, Holthe A, et al. Lean seafood intake reduces postprandial C-peptide and lactate concentrations in healthy adults in a randomized controlled trial with a crossover design. J Nutr. 2016;146:1027–34.
Douglas SM, Lasley TR, Leidy HJ. Consuming beef vs. soy protein has little effect on appetite, satiety, and food intake in healthy adults. J Nutr. 2015;145:1010–6. https://doi.org/10.3945/jn.114.206987
Hill AM, Harris Jackson KA, Roussell MA, West SG, Kris-Etherton PM. Type and amount of dietary protein in the treatment of metabolic syndrome: a randomized controlled trial. Am J Clin Nutr. 2015;102:757–70.
Van Nielen M, Feskens EJ, Rietman A, Siebelink E, Mensink M. Partly replacing meat protein with soy protein alters insulin resistance and blood lipids in postmenopausal women with abdominal obesity. J Nutr. 2014;144:1423–9.
Roussell MA, Hill AM, Gaugler TL, West SG, Vanden Heuvel JP, Alaupovic P, et al. Beef in an Optimal Lean Diet study: effects on lipids, lipoproteins, and apolipoproteins. Am J Clin Nutr. 2012;95:9–16.
Navas-Carretero S, Pérez-Granados AM, Schoppen S, Vaquero MP. An oily fish diet increases insulin sensitivity compared to a red meat diet in young iron-deficient women. Br J Nutr. 2009;102:546–53.
Azadbakht L, Kimiagar M, Mehrabi Y, Esmaillzadeh A, Padyab M, Hu FB, et al. Soy inclusion in the diet improves features of the metabolic syndrome: a randomized crossover study in postmenopausal women. Am J Clin Nutr. 2007;85:735–41.
Ouellet V, Marois J, Weisnagel SJ, Jacques H. Dietary cod protein improves insulin sensitivity in insulin-resistant men and women: a randomized controlled trial. Diabetes Care. 2007;30:2816–21.
Hodgson JM, Burke V, Beilin LJ, Puddey IB. Partial substitution of carbohydrate intake with protein intake from lean red meat lowers blood pressure in hypertensive persons. Am J Clin Nutr. 2006;83:780–7.
Kim Y, Keogh J, Clifton P. A review of potential metabolic etiologies of the observed association between red meat consumption and development of type 2 diabetes mellitus. Metabolism. 2015;64:768–79.
Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB. The role of iron in type 2 diabetes in humans. Biochm Biophys Acta Gen Subj. 2009;1790:671–81.
Van Nielen M, Feskens EJ, Mensink M, Sluijs I, Molina E, Amiano P, et al. Dietary protein intake and incidence of type 2 diabetes in Europe: the EPIC-InterAct Case-Cohort Study. Diabetes Care. 2014;37:1854–62.
Malik VS, Li Y, Tobias DK, Pan A, Hu FB. Dietary protein intake and risk of type 2 diabetes in US men and women. Am J Epidem. 2016;183:715–28.
Li W, Ruan W, Peng Y, Wang D. Soy and the risk of type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies. Diab Res Clin Pract. 2018;137:190–9.
Tang J, Wan Y, Zhao M, Zhong H, Zheng J-S, Feng F. Legume and soy intake and risk of type 2 diabetes: A systematic review and meta-analysis of prospective cohort studies. Am J Clin Nutr. 2020;111:677–88.
Ding M, Pan A, Manson J, Willett WC, Malik V, Rosner B, et al. Consumption of soy foods and isoflavones and risk of type 2 diabetes: a pooled analysis of three US cohorts. Eur J Clin Nutr. 2016;70:1381–7.
Valli C, Rabassa M, Johnston BC, Kuijpers R, Prokop-Dorner A, Zajac J, et al. Health-related values and preferences regarding meat consumption: a mixed-methods systematic review. Ann Intern Med. 2019;171:742–55.
Vernooij RW, Zeraatkar D, Han MA, El Dib R, Zworth M, Milio K, et al. Patterns of red and processed meat consumption and risk for cardiometabolic and cancer outcomes: a systematic review and meta-analysis of cohort studies. Ann Intern Med. 2019;171:732–41.
This research was funded by the Beef Checkoff and the funding sponsor provided comments on early aspects of the study design. A report was shared with the sponsor prior to submission, but the final decision for all aspects of study conduct and manuscript content are those of the authors alone.
LMS, MLW, and KCM are employees of Midwest Biomedical Research, which has received research funding from Beef Checkoff and National Pork Board.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sanders, L.M., Wilcox, M.L. & Maki, K.C. Red meat consumption and risk factors for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr 77, 156–165 (2023). https://doi.org/10.1038/s41430-022-01150-1